Achieve announces presentation of investigator-led rauora trial data demonstrating significantly fewer side effects with higher quit rates for cytisinicline (cytisine) compared to chantix® (varenicline) in first head-to-head comparative study

Seattle and vancouver, bc, sept. 18, 2020 /prnewswire/ -- achieve life sciences, inc. (nasdaq: achv), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced...
ACHV Ratings Summary
ACHV Quant Ranking